Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Hims offers convenient and affordable access to treatments and products tailored for men's health needs. But how much does it ...